Trials / Completed
CompletedNCT00861939
To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions
A Relative Bioavailability Study of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Sandoz · Industry
- Sex
- All
- Age
- 18 Years – 58 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to demonstrate the relative bioequivalence of Bupropion HCI 300 mg ER Tablets under fasting conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bupropion HCI 300 mg Extended-Release Tablets EON | |
| DRUG | WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2004-04-01
- Completion
- 2004-04-01
- First posted
- 2009-03-16
- Last updated
- 2017-03-29
Source: ClinicalTrials.gov record NCT00861939. Inclusion in this directory is not an endorsement.